Demonstrated hormetic mechanisms putatively subserve riluzole-induced effects in neuroprotection against amyotrophic lateral sclerosis (ALS): Implications for research and clinical practice

Edward J Calabrese; Vittorio Calabrese; James Giordano

doi:10.1016/j.arr.2021.101273

Demonstrated hormetic mechanisms putatively subserve riluzole-induced effects in neuroprotection against amyotrophic lateral sclerosis (ALS): Implications for research and clinical practice

Ageing Res Rev. 2021 May:67:101273. doi: 10.1016/j.arr.2021.101273. Epub 2021 Feb 8.

Authors

Edward J Calabrese¹, Vittorio Calabrese², James Giordano³

Affiliations

¹ Department of Environmental Health Sciences, Morrill I, N344, University of Massachusetts, Amherst, MA, 01003, USA. Electronic address: edwardc@schoolph.umass.edu.
² Department of Biomedical and Biotechnological Sciences, School of Medicine University of Catania, Via Santa Sofia 78, Catania, 95123, Italy. Electronic address: calabres@unict.it.
³ Departments of Neurology and Biochemistry, Georgetown University Medical Center, Washington, DC, 20057, USA. Electronic address: james.giordano@georgetown.edu.

PMID: 33571705
DOI: 10.1016/j.arr.2021.101273

Abstract

This paper provides evidence to support that riluzole, an FDA-approved treatment for amyotrophic lateral sclerosis (ALS), like many neuroprotective agents, displays and exerts hormetic biphasic dose responses. These findings have important implications for the experimental study and clinical treatment of ALS.

Keywords: ALS; Acquired resilience; Dose response; Hormesis; Neuroprotection; Riluzole.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

MeSH terms

Amyotrophic Lateral Sclerosis* / drug therapy
Humans
Neuroprotection
Neuroprotective Agents* / pharmacology
Riluzole / pharmacology

Substances

Neuroprotective Agents
Riluzole